

# STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-256) ROMLUSEVIMAB  
 PRONUNCIATION rom" loo sev' i mab  
 THERAPEUTIC CLAIM Treatment of SARS-CoV-2 infection

## CHEMICAL NAMES

1. Immunoglobulin G1 [254-tyrosine,256-threonine,258-glutamic acid], anti- (severe acute respiratory syndrome coronavirus 2 spike glycoprotein receptor-binding domain) (human monoclonal BR11-198  $\gamma$ 1-chain), disulfide with human monoclonal BR11-198  $\lambda$ -chain, dimer (Source: CAS)
2. Immunoglobulin G1-lambda2, anti- Severe acute respiratory syndrome coronavirus (SARS-CoV) [Spike glycoprotein (Peplomer protein)]; *Homo sapiens* monoclonal antibody;  $\gamma$ 1 heavy chain *Homo sapiens* (1-448) [VH (*Homo sapiens* IGHV7-4-1\*02 (96%) -(IGHD)-IGHJ6\*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1\*01 {CH2[M<sup>22</sup>>Y(254), S<sup>24</sup>>T(256), T<sup>26</sup>>E(258)], CH3[K<sup>107</sup>>del(449)]} (120-448)] (222-213')-disulfide with  $\lambda$ 2 light chain *Homo sapiens* (1'-214') [V-LAMBDA (*Homo sapiens* IGLV3-21\*01 (98%) - IGLJ2\*01)[6.3.11] (1'-108') -*Homo sapiens* IGLC2\*01 (109'-214')], dimer (228-228":231-231")-bisdisulfide, produced in CHO-K1 cell line, glycoform alfa (Source: USAN Program Chemical Consultant)

## STRUCTURAL FORMULA

### Heavy chains X & X''

|            |            |            |            |            |     |
|------------|------------|------------|------------|------------|-----|
| QVQLVQSGSE | LKKPGASVKV | SCKASGYTFT | TYVMNWVRQA | PGQGLEWMGW | 50  |
| INTNTGNPTY | AQGFTGRFVF | SLDTSVSTAS | LQISSLKAED | TAVYCSSEI  | 100 |
| TTLGGMDVWG | QGTTTVVSSA | STKGPSVFPL | APSSKSTSGG | TAALGCLVKD | 150 |
| YFPEPVTVSW | NSGALTSGVH | TFPAVLQSSG | LYSLSSVTV  | PSSSLGTQTY | 200 |
| ICNVNHKPSN | TKVDKKVEPK | SCDKTHTCPP | CPAPELLGGP | SVFLFPPKPK | 250 |
| DTLYITREPE | VTCVVVDVSH | EDPEVKFNWY | VDGVEVHNAK | TKPREEQYNS | 300 |
| TYRVVSVLTV | LHQDWLNGKE | YKCKVSNKAL | PAPIEKTISK | AKGQPREPQV | 350 |
| YTLPPSRDEL | TKNQVSLTCL | VKGFYPSDIA | VEWESNGQPE | NNYKTTTPVL | 400 |
| DSDGSFFLYS | KLTVDKSRWQ | QGNVFSQSV  | HEALHNHYTQ | KSLSLSPG   | 448 |


### Light chain X' & X'''

|            |            |            |            |            |      |
|------------|------------|------------|------------|------------|------|
| SYVLTQPPSV | SVAPGKTARI | TCGGNNIGSK | SVHWYQKPG  | QAPVLVIYYD | 50'  |
| SDRPSGIPER | FSGSNSGNTA | TLTISGVEAG | DEADYCCQVW | DSISDHRVFG | 100' |
| GGTKLTVLQ  | PKAAPSVTLF | PPSSEELQAN | KATLVCLISD | FYPGAVTVAW | 150' |
| KADSSPVKAG | VETTTPSKQS | NNKYAASSYL | SLTPEQWKSH | RSYSCQVTHE | 200' |
| GSTVEKTVAP | TECS       |            |            |            | 214' |

### Disulfide bridges location

|          |               |          |          |           |               |         |           |
|----------|---------------|----------|----------|-----------|---------------|---------|-----------|
| 22'-87"  | 22'''-87'''   | 22-96    | 22"-96"  | 136'-195' | 136'''-195''' | 146-202 | 146"-202" |
| 213'-222 | 213'''-222''' | 228-228" | 231-231" | 263-323   | 263'''-323''' | 369-427 | 369"-427" |

### Modified residues



### Glycosylation sites (N)

Asn-299 Asn-299''

## MOLECULAR FORMULA

C<sub>6354</sub>H<sub>9808</sub>N<sub>1676</sub>O<sub>202</sub>S<sub>40</sub> (nonglycosylated)

|                            |                              |
|----------------------------|------------------------------|
| MOLECULAR WEIGHT           | 142.99 kDa (nonglycosylated) |
| TRADEMARK                  | None as yet                  |
| SPONSOR                    | Brii Biosciences Inc.        |
| CODE DESIGNATIONS          | BR11-198                     |
| <u>CAS</u> REGISTRY NUMBER | 2509447-08-7                 |
| UNII                       | SM01RRU9KK                   |
| WHO NUMBER                 | 11992                        |

gbk